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TheWorld Health Organisation recommends outpatient influenza-like illness (ILI) and inpa-
tient severe acute respiratory illness (SARI) surveillance. We evaluated two influenza sur-
veillance systems in South Africa: one for ILI and another for SARI.
Methodology
The Viral Watch (VW) programme has collected virological influenza surveillance data vol-
untarily from patients with ILI since 1984 in private and public clinics in all 9 South African
provinces. The SARI surveillance programme has collected epidemiological and virological
influenza surveillance data since 2009 in public hospitals in 4 provinces by dedicated per-
sonnel. We compared nine surveillance system attributes from 2009–2012.
Results
We analysed data from 18,293 SARI patients and 9,104 ILI patients. The annual proportion
of samples testing positive for influenza was higher for VW (mean 41%) than SARI
(mean 8%) and generally exceeded the seasonal threshold from May to September (VW:
weeks 21–40; SARI: weeks 23–39). Data quality was a major strength of SARI (most data
completion measures>90%; adherence to definitions: 88–89%) and a relative weakness of
the VW programme (62% of forms complete, with limited epidemiologic data collected;
adherence to definitions: 65–82%). Timeliness was a relative strength of both systems (e.g.
both collected>93% of all respiratory specimens within 7 days of symptom onset). ILI
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surveillance was more nationally representative, financially sustainable and expandable
than the SARI system. Though the SARI programme is not nationally representative, the
high quality and detail of SARI data collection sheds light on the local burden and epidemiol-
ogy of severe influenza-associated disease.
Conclusions
To best monitor influenza in South Africa, we propose that both ILI and SARI should be
under surveillance. Improving ILI surveillance will require better quality and more systematic
data collection, and SARI surveillance should be expanded to be more nationally represen-
tative, even if this requires scaling back on information gathered.
Introduction
Annual influenza epidemics are estimated to cause 3–5 million cases of severe disease and
250,000–500,000 deaths globally, with the highest risk of severe disease occurring in adults
older than 65 years, children younger than 2 years, pregnant women, and persons with certain
medical conditions[1–2]. Seasonal influenza is an important viral cause of pneumonia in chil-
dren[3], and mortality rates due to pneumonia in children are highest in Africa[4].
Despite recent progress in describing the epidemiology and burden of influenza in sub-Sa-
haran Africa[5], most countries in this region lack longitudinal national surveillance data need-
ed to inform prevention and control strategies[6]. With little robust influenza data available,
the impact of the disease in this region remains poorly understood.
In South Africa, where influenza circulates seasonally during the Southern Hemisphere win-
ter[7], rates of seasonal influenza-related excess mortality in adults65 years have been esti-
mated to be at least three times higher than in the United States[8]. Widespread co-morbidities
such as human immunodeficiency virus (HIV) have also been identified as increasing the risk
of severe influenza-associated disease[9–10]. An interim report of influenza A(H1N1)pdm09
deaths in South Africa revealed that more than half occurred among individuals with HIV and
10% occurred in individuals with active tuberculosis[11].
Historically, influenza surveillance has been conducted through sentinel surveillance for in-
fluenza-like illness (ILI), with respiratory specimens being collected for virological monitoring
and vaccine strain selection. The 2009 influenza pandemic highlighted the need for improved
surveillance for severe influenza-associated disease and the use of standardized approaches to
data collection and reporting. In response to this need, several international organizations have
partnered with African governments to invest in the development of epidemiological and labo-
ratory influenza surveillance capacity.
The World Health Organization (WHO) now recommends countries to perform surveil-
lance for both ILI and influenza-associated severe acute respiratory infection (SARI), and that
surveillance systems undergo a comprehensive evaluation periodically, beginning 1–2 years
after implementation and before adding new sentinel sites[12]. To ensure national surveillance
objectives are being met, we conducted an evaluation and comparison of two influenza surveil-
lance systems in South Africa: a long-standing ILI system and a newer SARI system.
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Methods
Surveillance systems
We described the surveillance characteristics of the Viral Watch Programme and SARI surveil-
lance programmes (Table 1).
Viral Watch Programme. Established in 1984, the Viral Watch (VW) programme is an
active, prospective surveillance programme run by volunteer medical practitioners to monitor
outpatient influenza. ILI surveillance is performed at 205 sentinel sites in private and public
clinics in all 9 of South Africa’s provinces (Fig. 1)[7]. A case of ILI is defined as: an acute
respiratory infection with a measured fever (38°C), AND cough, AND onset within the past
7 days. Sites are requested to enrol patients with onset of symptoms within 72 hours of presen-
tation, and to enrol no more than 5 patients per week. Nose and throat swabs are collected
from consenting patients and most samples (>80%) are sent directly to the National Institute
for Communicable Diseases (NICD) for influenza testing by real-time reverse transcription
Table 1. Characteristics of the Viral Watch and severe acute respiratory infection (SARI) surveillance programmes.
Surveillance
characteristics
Viral Watch SARI Programme
Syndrome Influenza-like Illness (ILI) Severe acute respiratory infection (SARI)
Data collection Active, prospective, performed on a voluntary basis by
participating sentinel sites
Active, prospective, performed by dedicated personnel
In-patient vs. Out-
patient
Out-patient, ambulatory clinics In-patient, hospital-based
Public vs. Private Public and private* Public




Coordinating body National Institute for Communicable Diseases (NICD) National Institute for Communicable Diseases (NICD),
supported by CDC
Source of funding NICD NICD & CDC
Primarily virologic surveillance objectives: Both epidemiologic and virologic surveillance objectives:
Determine the relative contribution of influenza and other
respiratory pathogens to ILI
Determine the relative contribution of influenza and other
respiratory pathogens to SARI
Monitor the type and subtype of circulating influenza viruses
and other respiratory viruses
Monitor the type and subtype of circulating influenza viruses
and other respiratory viruses
Provide baseline data on the seasonality and distribution of
influenza and other respiratory viruses
Provide baseline data on the seasonality and distribution of
influenza and other respiratory viruses
Surveillance
objectives
Inform strain selection for the southern hemisphere influenza
vaccine
Describe trends in SARI incidence and case-fatality rates
Act as a platform for studying the effectiveness of influenza
vaccines
Describe the epidemiological characteristics of SARI cases
and identify high risk groups
Monitor antiviral sensitivity to inform the clinical use of antiviral
therapies
Describe the burden of SARI across age and risk groups
Detect novel respiratory viruses Estimate the severity of influenza epidemics
Monitor antiviral sensitivity to inform the clinical use of antiviral
therapies
Detect novel respiratory viruses
Act as a platform for studying the effectiveness of vaccines
* Most sentinel sites consist of private sector general practitioners, though primary care clinics, paediatric outpatient departments, and occupational health
clinics are also included.
doi:10.1371/journal.pone.0120226.t001
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polymerase chain reaction (rRT-PCR). Specimens from selected provinces are first tested for
influenza by shell viral culture at local laboratories, after which positive samples are shipped to
NICD for influenza subtyping by rRT-PCR. NICD is a current WHO National Influenza Cen-
tre[13] and VW is fully funded by NICD.
SARI Surveillance. SARI surveillance is performed by teams of dedicated personnel at
6 sentinel sites in public hospitals in 4 provinces (Fig. 1)[9]. Established in February 2009, this
active, prospective, hospital-based surveillance programme collects detailed epidemiological
and virological influenza surveillance data. In persons5 years of age, a case of SARI is defined
as: an acute respiratory infection with a history of fever or measured fever (38°C), AND
cough, AND onset within the past 7 days, AND requiring hospitalization. In children 3–59
months of age, a case of SARI is defined as physician-diagnosed lower respiratory tract infec-
tion (LRTI) with onset in the past 7 days and requiring hospitalization, while for infants aged
Fig 1. Map showing numbers of Viral Watch and SARI sentinel sites, by province 2012
doi:10.1371/journal.pone.0120226.g001
Influenza Surveillance in South Africa
PLOS ONE | DOI:10.1371/journal.pone.0120226 March 30, 2015 4 / 13
2 days to<3 months the definition includes suspected sepsis or LRTI irrespective of signs and
symptoms with onset in the past 7 days. All patients admitted on week days are eligible for en-
rolment, except adult patients at Chris Hani Baragwanath Hospital, where systematic sampling
is used on 2 of every 5 week days (selected days rotate) due to high patient load and resource
constraints. Specimens collected include nasopharyngeal aspirates from patients<5 years of
age and nasopharyngeal and throat swabs from patients5 years of age. Respiratory specimens
are transported on ice to NICD within 72 hours of collection and tested for 10 respiratory vi-
ruses, including influenza A and B viruses, by multiplex rRT-PCR[14]. Influenza virus subtypes
are also identified by rRT-PCR. The SARI programme is coordinated by NICD with financial
and technical assistance provided by the U.S. Centers for Disease Control and Prevention
(CDC).
Ethics Statement
The SARI surveillance protocol was approved by the Research Ethics Committees of the Uni-
versities of the Witwatersrand and KwaZulu-Natal. Ethical approval for the Viral Watch proj-
ect was obtained from the University of the Witwatersrand Research Ethics Committee. This
surveillance was deemed non-research by the U.S. CDC. Patient information was anonymized
and de-identified prior to analysis.
Evaluation and comparison of surveillance systems
I. Influenza seasonality and circulating strains. For each system we describe the weekly
proportion of samples testing positive for influenza, the week of peak detection, and season
start and end dates (seasonal threshold defined as influenza detection rates10% and<10%
for two consecutive weeks, respectively) from 2009 to 2012. The number of respiratory speci-
mens tested by week and the proportion testing positive for influenza and influenza types and
subtypes was also assessed. Only samples tested by rRT-PCR were included in our analysis.
II. Surveillance system attributes. CDC guidelines[15] suggest the usefulness of a surveil-
lance system is dependent on the actions that can be taken as a result of data collection and
analysis; specifically, whether the system is able to: (1) guide disease prevention and control ac-
tivities through the timely detection of adverse health-events, (2) estimate the magnitude of
morbidity and mortality and associated risk factors, (3) detect trends that signal changes in in-
cidence, including epidemics, (4) permit assessment of prevention and control measures, (5)
lead to improved health and social policy or clinical practice, and (6) stimulate research to in-
form prevention and control measures. Using criteria established by the CDC[15], we assessed
nine surveillance system attributes that can affect usefulness, including quantitative analyses of
data quality, timeliness, sensitivity, and positive predictive value, and qualitative descriptive
analyses of representativeness, simplicity, flexibility, acceptability, and stability.
Data quality was assessed by measuring the completeness of patient interview forms, form
transmission, respiratory specimen collection and testing, and by checking patient sign and
symptom records and primary diagnosis to determine whether surveillance case definitions
had been adhered to properly. Data collected by each system was also compared against mini-
mum data collection standards for ILI and SARI surveillance (S1 Table)[12].
Timeliness was assessed by measuring the duration of time for the collection, transfer, and
processing of forms and specimens, and for the availability of laboratory results.
Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV)
were obtained for one SARI and two ILI case definitions for predicting influenza infection
(Table 2). The clinical case definitions selected for this comparison included those used by each
Influenza Surveillance in South Africa
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system for screening and enrolment, and an older ILI case definition used by VW prior to
March 2012.
Results
I. Influenza seasonality and circulating strains
During 1 January 2009 to 31 December 2012, we analysed samples from 18,293 SARI patients
and 9,104 ILI patients. On average, the proportion of samples testing positive for influenza ex-
ceeded the seasonal threshold from May to September (VW: weeks 21–40 with mean peak in
week 30; SARI: weeks 23–39 with mean peak in week 31) and was consistently higher for VW
(mean 41%, mean annual range: 38–43%) than SARI (mean 8%, mean annual range: 5–11%)
in all four years analysed [relative risk (RR): 5.2, 95% CI: 5.0–5.5, p<.0001; Fig. 2]. Although
Table 2. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of selected SARI and ILI sign and symptom














Any child aged 2 days to < 3 months with (i) suspected
sepsis OR physician diagnosed LRTI irrespective of signs
and symptoms, AND (ii) onset within the past 7 days (in
use from February 2009 to present)










Any child aged 3–59 months with (i) LRTI, including
bronchiolitis or pneumonia or bronchitis or pleural
effusion, AND (ii) onset within the past 7 days (in use from
February 2009 to present)













Patients of all age groups, with (i) acute respiratory tract
infection of recent onset (within 72 hours), AND (ii)
sudden onset of fever, AND (iii) two or more of headache,
myalgia, cough, sore throat (in use from 2009 to February
2012)












Patients of all age groups, with an acute respiratory illness
with (i) measured fever of 38°C, AND (ii) cough, AND
(iii) onset within the past 7 days (in use from March 2012
to present)












*Only respiratory specimens collected during influenza seasons (May to September) were included in this analysis.
doi:10.1371/journal.pone.0120226.t002
Fig 2. Laboratory confirmed influenza detection rates, South Africa (2009–2012)*
doi:10.1371/journal.pone.0120226.g002
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neither system is used to estimate an epidemic threshold, both are considering doing so in
the future.
Weeks with small numbers of samples are prone to widely varying influenza detection
rates.
The circulating influenza strains detected were similar in proportion between VW and
SARI systems, except in 2011 when VW identified more A(H1N1)pdm09 (75%) and less influ-
enza B (11%) than SARI (A(H1N1)pdm09: 39%; influenza B: 36%) (S2 Table).
VW showed greater variability in the number of specimens tested per week (median 15,
interquartile range (IQR): 3–54) than the SARI system (median 94, IQR: 75–108), and unlike
SARI, VW specimen collection declined rapidly outside the annual influenza season (Fig. 3).
VW also tested fewer specimens per year (mean 2,276, range: 1,398–3,351) than SARI (mean
4,709, range: 3,658–5,202), though this may be partly due to the weekly enrolment limits placed
on VW sentinel sites.
II. Surveillance system attributes
The nine surveillance system attributes were analysed prior to the end of the 2012 influenza
season, using surveillance data collected between 01 January 2009 and 30 June 2012 from
15,271 SARI patients and 8,654 ILI patients.
The relative strengths and weaknesses of the SARI and VW systems are shown in Table 3.
Data Quality. The SARI system collects detailed epidemiological patient data; when com-
pared against minimum data collection standards for ILI and SARI surveillance (S1 Table), we
found patient interview forms contained all data elements recommended by WHO[12]. By
contrast, VW collects minimal epidemiological patient data. When compared against mini-
mum data collection standards for ILI surveillance, we found VW does not collect data on the
use of antivirals for current illness, or pre-existing conditions such as chronic neurological or
neuromuscular disease and haematological disorders.
Data quality was a major strength of the SARI system, with 40/43 key data elements on pa-
tient interview forms having completeness measures above 90% (n = 15,189 forms). Complete-
ness of other SARI forms (i.e., lab slips, Hospital Results Forms, Final Outcome Forms) were
similarly high, as were measures of form transmission (98% of enrolled patients had all surveil-
lance forms transferred from sentinel sites to NICD), data capturing (>99.9% of all forms re-
ceived at NICD were captured by data entry clerks), and specimen collection and testing (98%
of SARI patients had respiratory specimens collected and tested for influenza). Using available
data on primary diagnosis, adherence to the SARI case definition (S3 Table) in persons aged
2 days to<3 months was at least 89% (725/812) and adherence in persons aged 3–59 months
Fig 3. Number of respiratory specimens tested by week, South Africa (2009–2012).
doi:10.1371/journal.pone.0120226.g003
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was at least 88% (2,192/2,486). We were not able to evaluate adherence to the SARI case defini-
tion in persons aged 5 years or older because the appropriate data were not routinely collected
during the study timeframe.
Data quality was a relative weakness of VW. Over the four years analysed, 62% (n = 8,556)
of patient interview forms had complete data available for all data elements, though complete-
ness improved with new forms introduced in March 2012 (83% between April–June 2012, n =
698). Measures of specimen collection and testing were very high; 100% of ILI patients had re-
spiratory specimens collected and tested for influenza, and 99% (n = 2,667) of influenza A re-
sults were subtyped. Adherence to the ILI case definition in use from 2009 to March 2012 was
82% (n = 5,447), but decreased to 65% (n = 592) with the introduction of a new ILI case defini-
tion in March 2012.
Timeliness. Timeliness was a relative strength of the SARI programme; 93% (12,835/
13,813) of patients had respiratory specimens collected within 7 days of symptom onset (medi-
an: 3 days, IQR: 2–5 days), and 95% (13,291/14,020) of patients had respiratory specimens col-
lected within 1 day of hospital admission. The time interval from specimen collection to
capturing of results into analytic datasets at NICD was a median of 8 days (IQR: 7–11, n =
7,559). There were weaknesses, however; only 51% (7,770/15,243) of case investigation forms
were received at NICD within the programme target of 14 days after patient interviews (medi-
an: 14 days, IQR: 7–28).
Timeliness was also a relative strength of VW; 98% (n = 5,659) of ILI cases had respiratory
specimens collected within 7 days of symptom onset (median: 1 day), and the median time
from specimen collection to receipt at NICD is 1 day (n = 7,744). Once at NICD, however, the
median time to availability of laboratory results was 4 days (n = 612), which exceeded the pro-
gramme target by 1 day. Although case investigation forms for both systems are currently
paper-based, electronic data collection is being considered and may help to improve the timeli-
ness of future data transfer and capturing.
Sensitivity and PPV. The SARI programme’s SARI case definition in persons aged 2 days
to<3 months was introduced in February 2009 (S3 Table); using incorrectly enrolled patients
who did not meet the case definition as a comparator, we found the sensitivity of identifying
laboratory-proven influenza was high (89.6%; 95% CI: 82.4–94.1) and specificity (10.8%;
95% CI: 8.7–13.3) and PPV were low (13.1%; 95% CI: 10.8–15.8). Similarly, in children aged
Table 3. Strengths and limitations of surveillance attributes, SARI and Viral Watch surveillance programmes, South Africa.








Simplicity System design and ease of operation Major Strength Relative
Weakness
Flexibility Adaptability to changing information needs or operating conditions Major strength Relative Strength
Acceptability Willingness of persons and organizations to participate in system Relative Strength Relative strength
Stability Reliability and availability of the system Relative Strength Relative Strength
Data Quality Data completeness and validity Relative Weakness Major Strength
Timeliness Time interval between data reporting steps Relative Strength Relative Strength
Sensitivity The proportion of true cases detected by case definitions and diagnostic
tests
Relative Strength Relative Strength
Positive Predictive Value
(PPV)
Proportion of reported cases that are true cases Relative Strength Relative
Weakness
doi:10.1371/journal.pone.0120226.t003
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3–59 months, using enrolled patients who did not meet the case definition as a comparator, we
found sensitivity was high (94.3%; 95% CI: 91.4–96.2) and specificity (12.9%; 95% CI: 11.5–
14.4) and PPV were low (15.8%; 95% CI: 14.4–17.4). We were not able to evaluate sensitivity
and PPV of SARI case definitions in persons aged 5 years or older because the appropriate data
was not routinely collected during the study timeframe.
The VW’s current ILI case definition was introduced in March 2012 (S3 Table). Using in-
correctly enrolled patients who did not meet the case definition as a comparator, this slightly
improved sensitivity (89.7%; 95% CI: 88.3–90.9) and specificity (28.7%; 95% CI: 27.0–30.4) of
identifying laboratory-proven influenza compared with the ILI case definition in use prior to
March 2012 [sensitivity 88.7% (95% CI: 87.3–90.0), specificity 22.2% (95% CI: 20.7–23.8)]
(Table 2). PPV estimates were somewhat higher for ILI case definitions than for SARI, ranging
from 45.9% (95% CI: 44.4–47.4) for the ILI case definition in use before March 2012 to 48.3%
(95% CI: 46.8–49.9) for the definition VW now uses. Although they were not included in this
analysis, 18% (1,998/11,102) of VW specimens were first tested at local laboratories using less
sensitive viral culture techniques. Since only positive samples are shipped to NICD for subtyp-
ing by rRT-PCR, it is likely that true positives are being missed, though the system reports case
detections rates using samples tested at NICD only.
Representativeness. With public sentinel sites in just 4 out of 9 provinces, national repre-
sentativeness was a relative weakness of the SARI programme. Though its six public sector sen-
tinel sites were selected to represent a variety of geographic and demographic areas, the Cape
provinces (i.e. Western Cape, Eastern Cape, and Northern Cape) are not represented. By com-
parison, representativeness was a relative strength of VW. Although VW sample collection di-
minished rapidly outside the regular influenza season, VW has excellent geographic and
population coverage, with 205 sentinel sites servicing in all 9 provinces, including private sector
general practitioners, primary care clinics, paediatric outpatient departments, and occupational
health clinics.
Simplicity and Flexibility. Simplicity was relative weakness of the SARI programme; with
an annual operating cost of approximately $500,000–800,000 USD, the system requires sub-
stantial investments in human resources and the training of dedicated personnel. Though the
system collects extensive clinical and epidemiological data, it displays good flexibility, and has
adapted to changing information needs by enhancing surveillance at selected sites to include
patients with suspected or confirmed tuberculosis (TB) and patients with severe respiratory in-
fection (respiratory symptoms>7 days).
Simplicity is a major strength of VW; participation of sentinel sites is voluntary, data and
specimen collection materials are few, and minimal epidemiological data is collected. Laborato-
ry tests account for the majority of the programme’s operating costs (approximately $100,000
USD per annum), while coordination and overhead costs are low (approximately $20,000 USD
per annum) and can be scaled up or down as funds permit. VW also displays good flexibility,
and has expanded from fewer than 20 sentinel sites in 2005 to 205 sites in 2012 with little
growth in the programme’s overhead costs.
Acceptability and Stability. Indirect measures of acceptability include completeness and
timeliness of data reporting; on each account, the SARI programme performs well. Specimens
and forms are couriered to NICD to ensure transportation is timely and successful. Participa-
tion in the SARI programme is controlled through dedicated personnel and the high level of re-
sources supporting the programme ensure stability. The willingness of VW sentinel sites to
participate voluntarily suggests acceptability is also a relative strength of the programme,
though many do not send samples regularly. In 2011, 21% (42/202) of sites sent fewer than
5 samples in the entire year. The number of participating sites also supports programme
Influenza Surveillance in South Africa
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stability, though with few resources to support the system, VW specimens and forms are sent
to NICD via private laboratories used by participating clinicians.
Discussion
Surveillance for ILI and SARI is expanding rapidly in Africa; a review of 15 selected African
countries between 2006–2010 showed substantial increases in the number of surveillance sites
for both ILI (from 21 to 127) and SARI (from 2 to 98)[16]. For much of the past three decades,
South Africa’s influenza surveillance activities have focused primarily on virological monitor-
ing of mild influenza-associated disease. VW’s outpatient ILI surveillance was established to
serve this purpose, aiming to guide vaccine strain selection and monitor the type, seasonality,
and geographic distribution of influenza and other respiratory viruses. The system’s core
strengths, especially national representativeness, support these objectives, though its reliance
on voluntary practitioners limits the quality of data collected and VW is actively working to
limit its sites to clinics that are performing well as part of the network. The recent establish-
ment of SARI surveillance was intended to address the need for improved epidemiologic and
virological monitoring of severe influenza-associated disease. Though the SARI programme is
not nationally representative, the high quality and detail of data collected sheds light on the
local burden and epidemiology of SARI, which is especially relevant from a clinical and public
health standpoint and may be better suited to address questions of public health priority in
South Africa.
With 30-years of historical seasonal influenza data, VW has helped to characterise seasonal
influenza trends in South Africa[7]. Importantly, its lower operating costs are sustainable in an
environment of competing health priorities and limited resources. This study has shown VW
also detects the influenza season sooner than SARI, an advantage that can help to better inform
the timing of national prevention and treatment policies, such as vaccination periods and the
use of pharmaceutical and non-pharmaceutical interventions to control spread. With higher
influenza detection rates than SARI, VW is also more efficient from the standpoint of laborato-
ry testing, though it tests for fewer pathogens. Data quality was a relative weakness however.
Without dedicated personnel at sentinel sites, patient interview forms were frequently incom-
plete and adherence to the ILI case definition in use since March 2012 was poor when it was
first introduced. VW specimen collection also falls rapidly outside the regular influenza season.
Without systematic data collection, the number of specimens collected may reflect numbers of
participating sentinel sites rather than the intensity of influenza transmission, limiting its abili-
ty to establish reliable baseline levels of activity. This makes it difficult to accurately identify the
end of the influenza season. Also, like SARI the VW programme does not estimate an epidemic
threshold, though both are considering doing so and this would be a useful addition in the
future.
The SARI system’s primary strength, data quality and depth, supports the programme in
meeting its many surveillance objectives, which depend heavily on detailed epidemiological pa-
tient data. Understanding the local burden of SARI and the underlying risk conditions associat-
ed with severe disease and the use of health care resources is particularly important for clinical
and public health decision making. For example, this information can be used to improve pre-
vention and clinical management in high risk patients by prioritizing patients for vaccination
and treatment[9]. It also allows for the study of the interaction between influenza and other
priority diseases such as pneumonia, HIV[9] and TB[17]. With stable, year-round specimen
collection, the system also provides data needed to establish historical trends, set epidemic
thresholds, and understand the relation between virus strain and disease severity. This
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information can be used to rapidly assess the severity of each influenza season and unexpected
events, as the recent A(H1N1)pdm09 pandemic demonstrated. The number of SARI specimens
collected also reflects the burden of pneumonia, though this has many viral and bacterial aetiol-
ogies, each with different seasonalities. The system may also be used as a research platform for
economic evaluations, though economic data is not routinely gathered.
Despite its many strengths, the SARI system has a few notable weaknesses; during the
course of this evaluation, sentinel sites were located in just 4 of 9 provinces (excluding all of the
Cape provinces), limiting its national representativeness. With its high operating costs and a
history of dependence on external financial support, the long-term financial sustainability of
the system has been uncertain. Encouragingly, the South Africa government has recently
started supporting SARI surveillance. By acting as a platform for the surveillance of other respi-
ratory illnesses, including tuberculosis and respiratory syncytial virus (RSV) infection, the
SARI system integrates influenza surveillance with a broader approach to respiratory disease
surveillance. This has several benefits: it allows for efficiencies in data collection and laboratory
transport, and is a more efficient use of resources. These widespread benefits enhance the use-
fulness of the system as it meets its own surveillance objectives and broader national priorities.
To improve national representativeness, expansion of the system may be required, although
fewer sustainable sentinel sites should be preferred over a geographically widespread, but
under-resourced, national network.
The choice of clinical case definition for influenza surveillance will depend on programme
objectives; systems such as VW that aim to track seasonal influenza activity and collect virus
isolates with limited resources may wish to maximize specificity, while systems such as SARI
that are designed to estimate disease burden may wish to identify all influenza cases in a specif-
ic population and therefore prefer a more sensitive case definition. Previous studies have iden-
tified wide ranging sensitivity and specificity estimates for ILI [18–22], though varying
populations and study designs limit direct comparability. VW’s current ILI case definition was
found to be more specific than the definition previously used by the programme, which should
help to reduce the number of specimens needed for each positive influenza case identified. The
SARI case definitions for children age 2 days to<3 months and 3–59 months were more sensi-
tive and less specific than estimates recently reported in children aged 2–59 months in Kenya
[22].
The balance between surveillance for mild and severe influenza-associated disease should be
determined by the information needs and priorities of each country. In settings with limited
laboratory capacity, it may be desirable to test for influenza using a subset of ILI and SARI pa-
tients while gathering epidemiological data from a larger number of sites. With both the VW
and SARI systems active, it is possible to study the contribution of influenza to both outpatient
and inpatient respiratory disease. To meet long standing virological surveillance objectives—
namely to determine the timing of the annual influenza seasons, conduct resistance testing and
inform vaccine strain selection—it is not necessary to collect extensive epidemiological infor-
mation or employ systematic sampling methods. However, the epidemiologic and virological
monitoring of severe respiratory disease provides national benefits that are worth the added in-
vestment. In line with WHO recommendations[12], we propose that both outpatient ILI and
hospitalized SARI should be under surveillance in South Africa to best monitor influenza activ-
ity. ILI surveillance should be limited to sites that are currently preforming well as part of the
network and improved to be more systematically gathered, and SARI surveillance should be ex-
panded to be more nationally representative, even if this requires scaling back on information
gathered and numbers of specimens tested.
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